COX-2 selective inhibitor is a form of Non-steroidal anti-inflammatory drug (NSAID) that directly targets COX-2, an enzyme responsible for inflammation and pain.
Selectivity for COX-2 reduces the risk of peptic ulceration, and is the main feature of celecoxib, rofecoxib and other members of this drug class.
Cox-2-selectivity does not seem to affect other side-effects of NSAIDs (most notably an increased risk of renal failure), and some results have aroused the suspicion that there might be an increase in the risk for heart attack, thrombosis and stroke by a relative increase in thromboxane.
Rofecoxib was taken off the market in 2004 because of these concerns.
For more information about the topic COX-2 inhibitor, read the full article at Wikipedia.org, or see the following related articles:
Editor's Note: This article is not intended to provide medical advice, diagnosis or treatment.
Recommend this page on Facebook, Twitter,
and Google +1:
Other bookmarking and sharing tools: